NCT02712372View on ClinicalTrials.gov

A Study to Assess the Safety and Tolerability of Single and Multiple Doses of AZD4831 in Healthy Male Subjects

PHASE1TerminatedINTERVENTIONAL
Enrollment

104

Participants

Timeline

Start Date

June 30, 2016

Primary Completion Date

October 31, 2016

Study Completion Date

October 31, 2016

Conditions
Cardiovascular Disease
Interventions
DRUG

AZD4831

AZD4831 1-50 mg/g oral suspension

DRUG

AZD4831 placebo

AZD4831 placebo oral suspension

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY